# Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC

> **NCT03624231** · PHASE2 · COMPLETED · sponsor: **Ulrich Keilholz** · enrollment: 18 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT03624231
- **Lead sponsor:** Ulrich Keilholz
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-15
- **Primary completion:** 2023-08-17
- **Final completion:** 2023-08-17
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-08-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03624231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03624231, "Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03624231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*